吉西他滨与多西他赛联合顺铂治疗晚期NSCLC的临床研究  

Clinical Observation of Gemcitabine Combined With Cisplatin Versus Docetaxel Combined With Cisplatin in the Treatment for Patients with Advanced NSCLC

作　　者：张宇飞[1] 安晓静[1] 马风梅[1] 

机构地区：[1]中国人民解放军济南军区第88医院呼吸内科,泰安271000

出　　处：《成都医学院学报》2013年第1期21-22,31,共3页Journal of Chengdu Medical College

基　　金：国家自然科学基金(NO:81000022)

摘　　要：目的研究比较吉西他滨与多西他赛联合顺铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法将72例晚期NSCLC患者随机分成两组,分别接受吉西他滨与多西他赛联合顺铂化疗,每例患者至少接受2个周期以上的同一方案治疗,比较两组方案治疗的近期疗效、不良反应及1年生存期。结果吉西他滨联合顺铂化疗组有效率为47.2%,多西他赛联合顺铂化疗组有效率为44.5%;吉西他滨联合顺铂化疗组患者中位生存期11.4个月,1年生存率为44.5%,多西他赛联合顺铂化疗组患者中位生存期11.1个月,1年生存率41.7%,两组的各项结果比较差异均无统计学意义(P>0.05)。结论吉西他滨与多西他赛联合顺铂方案治疗晚期NSCLC疗效相似,可以作为临床一线治疗方案。Objective To compare the efficacy of gemcitabine combined with cisplatin versus docetaxel combined with cisplatin in advanced non-small cell lung cancer （NSCLC）, respectively. Methods A total of 72 patients with advanced NSCLC were randomized into two groups： one group were treated with gemcitabine and cisplatin,and the other group was treated with decetaxel and cisplatin. Each patient received 2 cycles chemotherapy at least. The short-term effect, side effects, median survival time and 1-year survival rate were evaluated after chemotherapy. Results The short-term response rates in gemcitabine combined with cisplatin versus docetaxel combined with cisplatin were 47.2 %and 44.5% respectively, 1-year survival rates were 44.5 % and 41.7%, and the median survival time was 11.4 months and 11.1 months respectively. No significant difference was observed between the two groups（P〉0.05）. Conclusion Regimens of gemcitabine combined with cisplatin and docetaxel combined with cisplatin are both safe and effective in the treatment of advanced NSCLC. They can be used as the first regimen of chemotherapy in patients with advanced NSCLC.

关 键 词：吉西他滨 紫杉醇 顺铂 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]